Glucagon-Like Peptide-1 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms.
Diabetes medications unexpectedly reduce cravings in patients with cocaine addiction, suggesting a new therapeutic avenue.
This French pharmacovigilance and mechanistic review reports clinical observations of GLP-1 RA use in cocaine use disorder patients, noting unexpected reductions in craving and use that parallel prior observations in alcohol and nicotine disorders. The underlying dopaminergic mechanisms in the nucleus accumbens are reviewed, supporting the hypothesis that GLP-1 receptors modulate reward circuitry in ways applicable to multiple substance use disorders.
What the study was
- Study design
- Clinical observation study with mechanistic review
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Fundam Clin Pharmacol
Why it surfaced
GLP-1 RA for substance use disorder is an emerging cross-indication signal with major public health implications; cocaine use disorder has essentially no approved pharmacotherapy; novel mechanism + clinical observation; relevant to GLP-1 watchlist expansion.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.